Sarepta Therapeutics traded at $17.55 this Friday May 15th, decreasing $1.13 or 6.05 percent since the previous trading session. Looking back, over the last four weeks, Sarepta Therapeutics lost 17.10 percent. Over the last 12 months, its price fell by 51.83 percent. Looking ahead, we forecast Sarepta Therapeutics to be priced at 19.54 by the end of this quarter and at 18.35 in one year, according to Trading Economics global macro models projections and analysts expectations.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.